Stephen Wade, MD
Pain Medicine · Utica, NYNPI 1114067261
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,822 of the $15,773 with a category attached, or 62.3%. It is spread thinly across 26 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2019 at $6,807 and has fallen 61.1% since, to $2,646 in 2025.
Across 268 payments — averaging $58.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$3K
- Boston Scientific$3K
- Saluda Medical Americas, Inc.$2K
- Abbott$2K
- Bioventus LLC$1K
- Pacira Pharmaceuticals Incorporated$698
- plus $3K from 20 others
What the payments were for
- Travel & lodging$5,95138%
- Food & beverage$9,82262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 52 | $3,355 |
| Boston Scientific | 32 | $2,837 |
| Saluda Medical Americas, Inc. | 8 | $2,473 |
| Abbott | 33 | $1,921 |
| Bioventus LLC | 7 | $1,380 |
| Pacira Pharmaceuticals Incorporated | 5 | $698 |
| Johnson & Johnson | 6 | $631 |
| Globus Medical | 8 | $418 |
| Collegium Pharmaceutical, Inc. | 33 | $365 |
| Si-bone, Inc. | 6 | $358 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 37 | $207 |
| Sentynl Therapeutics, Inc. | 14 | $189 |
| Zimmer Biomet | 2 | $169 |
| Curonix LLC | 1 | $137 |
| Zimvie Inc. | 1 | $117 |
| Medtronic | 1 | $107 |
| Relievant Medsystems, Inc. | 1 | $85 |
| Biodelivery Sciences International, Inc. | 5 | $67 |
| Kowa Pharmaceuticals America, Inc. | 3 | $57 |
| Vertex | 2 | $50 |
| Scilex Pharmaceuticals Inc. | 3 | $43 |
| MDD US Operations, LLC | 2 | $29 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Amgen | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evoke$2,102
- Senza Spinal Cord Stimulation System$1,762
- Durolane$1,280
- Proclaim Family of SCS IPGs$920
- ORTHOVISC$612
- Iovera$563
- Senza$513
- GENERAL PAIN MANAGEMENT$263
- Evoke SCS$184
- iFuse Implant$167
- Axium INS DRG IPG$148
- Biomet SpinalPak / OrthoPak$144
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$137
- Axium Sheath Braided DRG$133
- PROCLAIM$129
- Omnia$124
- MONOVISC$118
- Biomet EBI Bone Healing System$117
- O-ARM$107
How this compares
$15,773 in reported general payments places this provider in the 85th percentile of 503 pain medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 256 | $12,429 |
| NucyntaTapentadol Hcl | 12 | $7,972 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 360 | $6,398 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 28 | $6,154 |
| Gabapentin | 589 | $5,725 |
| Cyclobenzaprine Hcl | 384 | $2,506 |
| Pregabalin | 44 | $2,486 |
| Lidocaine | 14 | $2,420 |
| Tizanidine Hcl | 137 | $2,316 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 41 | $1,295 |
| Tramadol Hcl | 301 | $1,211 |
| Naloxone Hcl | 16 | $973 |
| Morphine Sulfate | 18 | $510 |
| Morphine Sulfate ErMorphine Sulfate | 23 | $503 |
| Nortriptyline Hcl | 43 | $429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta | $365 | $7,97212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 503 pain medicine providers in New York.
Other pain medicine in Utica
- Gary SchwartzBrooklyn$756K
- Amitabh GulatiNew York$614K
- William CaldwellStony Brook$530K
- Brian DurkinPort Jefferson$455K
- David SpinnerNew York$391K
- Grace FordeNew Hyde Park$355K
- Romanth WaghmaraeHamburg$158K
- Samuel BrownSouthold$147K
- Fred CohenBronx$141K
- Eric LeeNew York$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.